40,000 oncologists gave a standing ovation to a survival curve at ASCO 2026. That does not happen. Here is why it did.
RASolute 302 enrolled 500 patients with metastatic pancreatic cancer - a disease where 5-year survival is around 3% once it spreads. The result: 13.2 months median OS on daraxonrasib vs 6.7 months on chemo. Hazard ratio 0.40. That is rou…
